Showing 8651-8660 of 18131 results for "".
- New siRNA Therapy for Benign Lesions Could Reduce Risk for Future Cancerhttps://reachmd.com/news/new-sirna-therapy-benign-lesions-precursor-cancer/2467089/Researchers have developed a novel genetic therapy for reversing the formation of giant moles in patients with congenital melanocytic naevus syndrome (CMN), thereby also reducing their risk for developing melanoma later on. The therapy for this rare condition works by suppressing the NRAS
- Researchers Turn Back the Clock on Cancer Cells to Offer New Treatment Paradigmhttps://reachmd.com/news/researchers-turn-back-the-clock-on-cancer-cells-to-offer-new-treatment-paradigm/2462504/St. Jude Children’s Research Hospital scientists reversed an aggressive cancer, reverting malignant cells towards a more normal state. Rhabdoid tumors are an aggressive cancer which is missing a key tumor suppressor protein. Findings showed that with the missing tumor
- Retinal Vein Occlusion in Europe: New Data Links the Condition to Long-Term Mortality Riskhttps://reachmd.com/news/retinal-vein-occlusion-in-europe-new-data-links-the-condition-to-long-term-mortality-risk/2483508/Retinal vein occlusion (RVO) is widely known as a leading cause of visual impairment, second only to diabetic retinopathy among retinal vascular diseases. But new findings from the Gutenberg
- How AI-Powered Hydrogel Dressings are Revolutionizing Chronic Wound Carehttps://reachmd.com/news/how-ai-powered-hydrogel-dressings-are-revolutionizing-chronic-wound-care/2483411/An emerging generation of smart wound dressings that combine conductive hydrogel technology with artificial intelligence (AI) is showing promise in the management of refractory wounds—a category that includes pressure ulcers, diabetic ulcers, and joint-related inju
- Noninvasive Diagnostic Techniques for Pancreatic Tumorshttps://reachmd.com/news/noninvasive-diagnostic-techniques-for-pancreatic-tumors/2474815/Advancements in noninvasive imaging are fundamentally altering the diagnostic landscape for pancreatic tumors. As Diabetes and Endocrinology now place a significant emphasis on biomarkers and insulinoma detection, and Radiology harnesses tools like 18F-exendin-4 PE
- The Role of Circadian Rhythm Disruption in Metabolic Diseasehttps://reachmd.com/news/the-role-of-circadian-rhythm-disruption-in-metabolic-disease/2474243/Muscle tissue circadian rhythm disruptions and suboptimal dietary habits may significantly contribute to metabolic pathologies, including diabetes, highlighting critical lifestyle factors interplaying with metabolic regulation. Exploring the In
- Revolutionizing Chronic Disease Management Through Personalized Approacheshttps://reachmd.com/news/revolutionizing-chronic-disease-management-through-personalized-approaches/2471489/Chronic diseases like diabetes and irritable bowel syndrome (IBS) present ongoing challenges for healthcare professionals and patients alike. Recent studies emphasize the importance of personalized management strategies to improve outcomes. Tec
- Revolutionizing Healthcare Through Telemedicine and Mitochondrial Researchhttps://reachmd.com/news/revolutionizing-healthcare-through-telemedicine-and-mitochondrial-research/2471488/Recent advancements in telemedicine and mitochondrial research are paving the way for improved healthcare access and potential cures for diabetes, offering new hope for patients and healthcare professionals alike. Telemedicine: A New Era in Rur
- Exploring Empagliflozin's Role in Managing Heart Health Riskshttps://reachmd.com/news/exploring-empagliflozins-role-in-managing-heart-health-risks/2471269/Recent studies have provided new insights into how empagliflozin, a medication primarily used for diabetes, impacts heart health, particularly following heart attacks. While showing promise in reducing certain risks, the ov
- Unraveling the Biomarkers of Prediabetes Trajectorieshttps://reachmd.com/news/unraveling-the-biomarkers-of-prediabetes-trajectories/2471146/Exploring the proteomic and metabolomic signatures can shed light on why some individuals with prediabetes progress to diabetes while others revert to normoglycemia within a year, offering potential biomarkers for predicting these outcomes. Und